Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a Randomised, Double Blind, Placebo-controlled Clinical Study
Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG
Published in Experimental and Clinical Endocrinology & Diabetes
Abstract
Randomised, double blind, placebo-controlled trial of benfotiamine in diabetic polyneuropathy.
Key Findings
Benfotiamine 600 mg/day improved neuropathy symptom score versus placebo over 6 weeks, with the higher dose showing the clearest effect.
Conclusions
Benfotiamine, a lipid-soluble thiamine derivative, may reduce diabetic polyneuropathy symptoms.
Limitations
Short duration, symptom-score primary endpoint, industry involvement.
Supplements Studied
Benfotiamine 600 mg/day improved neuropathy symptom score versus placebo over 6 weeks, with the higher dose showing the clearest effect.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.